Myriad Genetics (MYGN) announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Noting that Ambry is a profitable testing laboratory that generates more than $300 million of revenue annually, the investment bank thinks that the deal will enable TEM to start generating positive ...

The Greater Middle East is home to a rich genetic diversity that remains largely untapped in genomic research. This Perspective explores its potential for rare disease research, obstacles limiting ...

New Delhi [India] / London [UK] / Munich [Germany], January 28: Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by ...

New Delhi [India] / London [UK] / Munich [Germany], January 28: Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by ...

This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. Tracking genomic variants across multiple time points in the same ...

BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled ...